J-code: Drugs administered other than oral method; chemotherapy drugs Drugs administered other than oral method; chemotherapy drugs
1,255 codes
Billing context
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| J8522 | Capecitabine, oral, 50 mg | $0.029per 50 MG | Oct 1, 2024 | Active |
| J8530 | Cyclophosphamide; oral, 25 mg | $1.233per 25 MG | Jan 1, 1995 | Active |
| J8540 | Dexamethasone, oral, 0.25 mg | $0.022per 0.25 MG | Jan 1, 2006 | Active |
| J8541 | Dexamethasone (hemady), oral, 0.25 mg | $0.375per 0.25 MG | Oct 1, 2024 | Active |
| J8560 | Etoposide; oral, 50 mg | $88.164per 50 MG | Jan 1, 1995 | Active |
| J8562 | Fludarabine phosphate, oral, 10 mg | — | Jan 1, 2011 | Ended Dec 31, 2025 |
| J8565 | Gefitinib, oral, 250 mg | — | Jan 1, 2005 | Active |
| J8597 | Antiemetic drug, oral, not otherwise specifiedNOC / NOS | — | Jan 1, 2006 | Active |
| J8600 | Melphalan; oral, 2 mg | — | Jan 1, 1995 | Active |
| J8610 | Methotrexate; oral, 2.5 mg | $0.157per 2.5 MG | Jan 1, 1995 | Active |
| J8611 | Methotrexate (jylamvo), oral, 2.5 mg | $18.264per 2.5 MG | Jul 1, 2024 | Active |
| J8612 | Methotrexate (xatmep), oral, 2.5 mg | $22.855per 2.5 MG | Jul 1, 2024 | Active |
| J8650 | Nabilone, oral, 1 mg | — | Jan 1, 2007 | Ended Dec 31, 2025 |
| J8655 | Netupitant 300 mg and palonosetron 0.5 mg, oral | $455.762per 0.5 MG | Jan 1, 2016 | Active |
| J8670 | Rolapitant, oral, 1 mg | — | Jan 1, 2017 | Active |
| J8700 | Temozolomide, oral, 5 mg | $0.208per 5 MG | Jan 1, 2001 | Active |
| J8705 | Topotecan, oral, 0.25 mg | $125.461per 0.25 mg | Jan 1, 2009 | Active |
| J8999 | Prescription drug, oral, chemotherapeutic, nosNOC / NOS | — | Jan 1, 1995 | Active |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | $3.120per 10 MG | Jan 1, 1984 | Active |
| J9003 | Leuprolide injectable (camcevi etm), 1 mg | — | Apr 1, 2026 | Active |
| J9010 | Injection, alemtuzumab, 10 mg | — | Jan 1, 2003 | Ended Dec 31, 2015 |
| J9011 | Injection, datopotamab deruxtecan-dlnk, 1 mg | $52.505per 1 MG | Oct 1, 2025 | Active |
| J9015 | Injection, aldesleukin, per single use vial | — | Jan 1, 1996 | Active |
| J9017 | Injection, arsenic trioxide, 1 mg | $3.837per 1 MG | Jan 1, 2002 | Active |
| J9019 | Injection, asparaginase (erwinaze), 1,000 iu | — | Jan 1, 2013 | Ended Dec 31, 2025 |
| J9020 | Injection, asparaginase, not otherwise specified, 10,000 unitsNOC / NOS | — | Jan 1, 1984 | Ended Dec 31, 2025 |
| J9021 | Injection, asparaginase, recombinant, (rylaze), 0.1 mg | $59.042per 0.1 MG | Jan 1, 2022 | Active |
| J9022 | Injection, atezolizumab, 10 mg | $96.873per 10 MG | Jan 1, 2018 | Active |
| J9023 | Injection, avelumab, 10 mg | $108.994per 10 MG | Jan 1, 2018 | Active |
| J9024 | Injection, atezolizumab, 5 mg and hyaluronidase-tqjs | $32.419per 5 MG | Apr 1, 2025 | Active |
| J9025 | Injection, azacitidine, 1 mg | $0.269per 1 MG | Jan 1, 2006 | Active |
| J9026 | Injection, tarlatamab-dlle, 1 mg | $1,613.751per 1 MG | Jan 1, 2025 | Active |
| J9027 | Injection, clofarabine, 1 mg | $15.518per 1 MG | Jan 1, 2006 | Active |
| J9028 | Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram | $94.139per 1 MCG | Jan 1, 2025 | Active |
| J9029 | Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose | $65,200.563per PER THERAPEUTIC DOSE | Jul 1, 2023 | Active |
| J9030 | Bcg live intravesical instillation, 1 mg | $3.532per 1 MG | Jul 1, 2019 | Active |
| J9031 | Bcg (intravesical) per instillation | — | Jan 1, 1991 | Ended Jun 30, 2019 |
| J9032 | Injection, belinostat, 10 mg | $55.526per 10 MG | Jan 1, 2016 | Active |
| J9033 | Injection, bendamustine hydrochloride, not otherwise specified, 1 mgNOC / NOS | $1.846per 1 MG | Jan 1, 2009 | Active |
| J9034 | Injection, bendamustine hcl (bendeka), 1 mg | $11.422per 1 MG | Jan 1, 2017 | Active |
| J9035 | Injection, bevacizumab, 10 mg | $75.492per 10 MG | Jan 1, 2005 | Active |
| J9036 | Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg | $9.264per 1 MG | Jul 1, 2019 | Active |
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg | — | Apr 1, 2021 | Ended Mar 31, 2025 |
| J9038 | Injection, axatilimab-csfr, 0.1 mg | $56.498per 0.1 MG | Apr 1, 2025 | Active |
| J9039 | Injection, blinatumomab, 1 microgram | $173.047per 1 MCG | Jan 1, 2016 | Active |
| J9040 | Injection, bleomycin sulfate, 15 units | $23.120per 15 UNITS | Jan 1, 1984 | Active |
| J9041 | Injection, bortezomib, 0.1 mg | $2.628per 0.1 MG | Jan 1, 2005 | Active |
| J9042 | Injection, brentuximab vedotin, 1 mg | $279.207per 1 MG | Jan 1, 2013 | Active |
| J9043 | Injection, cabazitaxel, 1 mg | $231.688per 1 MG | Jan 1, 2012 | Active |
| J9044 | Injection, bortezomib, not otherwise specified, 0.1 mgNOC / NOS | — | Jan 1, 2019 | Ended Dec 31, 2022 |
| J9045 | Injection, carboplatin, 50 mg | $3.101per 50 MG | Jan 1, 1990 | Active |
| J9046 | Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg | — | Jan 1, 2023 | Active |
| J9047 | Injection, carfilzomib, 1 mg | $60.391per 1 MG | Jan 1, 2014 | Active |
| J9048 | Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg | — | Jan 1, 2023 | Active |
| J9049 | Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg | $1.531per 0.1 MG | Jan 1, 2023 | Active |
| J9050 | Injection, carmustine, 100 mg | $195.730per 100 MG | Jan 1, 1984 | Active |
| J9051 | Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg | — | Oct 1, 2023 | Active |
| J9052 | Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg | — | Jan 1, 2024 | Active |
| J9053 | Injection, belantamab mafodotin-blmf, 0.1 mg | $36.201per 0.1 MG | Jul 1, 2026 | Active |
| J9054 | Injection, bortezomib (boruzu), 0.1 mg | $23.905per 0.1 MG | Apr 1, 2025 | Active |
| J9055 | Injection, cetuximab, 10 mg | $80.858per 10 MG | Jan 1, 2005 | Active |
| J9056 | Injection, bendamustine hydrochloride (vivimusta), 1 mg | $28.614per 1 MG | Jul 1, 2023 | Active |
| J9057 | Injection, copanlisib, 1 mg | — | Jan 1, 2019 | Active |
| J9058 | Injection, bendamustine hydrochloride (apotex), 1 mg | — | Jul 1, 2023 | Ended Dec 31, 2024 |
| J9059 | Injection, bendamustine hydrochloride (baxter), 1 mg | — | Jul 1, 2023 | Ended Dec 31, 2024 |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | $2.497per 10 MG | Jan 1, 1984 | Active |
| J9061 | Injection, amivantamab-vmjw, 2 mg | $23.622per 2 MG | Jan 1, 2022 | Active |
| J9062 | Injection, amivantamab 5 mg and hyaluronidase-lpuj | $40.492per 5 MG | Jul 1, 2026 | Active |
| J9063 | Injection, mirvetuximab soravtansine-gynx, 1 mg | $71.584per 1 MG | Jul 1, 2023 | Active |
| J9064 | Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg | — | Oct 1, 2023 | Active |
| J9065 | Injection, cladribine, per 1 mg | $7.872per 1 MG | Jan 1, 1995 | Active |
| J9066 | Injection, bendamustine hydrochloride (avyxa), 1 mg | — | Oct 1, 2026 | Active |
| J9070 | Cyclophosphamide, 100 mg | — | Jan 1, 1984 | Ended Mar 31, 2024 |
| J9071 | Injection, cyclophosphamide (auromedics), 5 mg | $0.471per 5 MG | Apr 1, 2022 | Active |
| J9072 | Injection, cyclophosphamide (frindovyx), 5 mg | $8.120per 5 MG | Jan 1, 2024 | Active |
| J9073 | Injection, cyclophosphamide (dr. reddy's), 5 mg | $0.465per 5 MG | Apr 1, 2024 | Active |
| J9074 | Injection, cyclophosphamide (sandoz), 5 mg | $3.238per 5 MG | Apr 1, 2024 | Active |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mgNOC / NOS | $0.692per 5 MG | Apr 1, 2024 | Active |
| J9076 | Injection, cyclophosphamide (baxter), 5 mg | $4.601per 5 MG | Jan 1, 2025 | Active |
| J9098 | Injection, cytarabine liposome, 10 mg | — | Jan 1, 2004 | Ended Dec 31, 2025 |
| J9100 | Injection, cytarabine, 100 mg | $0.853per 100 MG | Jan 1, 1986 | Active |
| J9118 | Injection, calaspargase pegol-mknl, 10 units | $86.179per 10 UNIT | Oct 1, 2019 | Active |
| J9119 | Injection, cemiplimab-rwlc, 1 mg | $30.825per 1 MG | Oct 1, 2019 | Active |
| J9120 | Injection, dactinomycin, 0.5 mg | $320.899per 0.5 MG | Jan 1, 1984 | Active |
| J9130 | Dacarbazine, 100 mg | $3.581per 100 MG | Jan 1, 1986 | Active |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | $57.973per 10 MG | Jan 1, 2021 | Active |
| J9145 | Injection, daratumumab, 10 mg | $75.228per 10 MG | Jan 1, 2017 | Active |
| J9150 | Injection, daunorubicin, 10 mg | $26.912per 10 MG | Jan 1, 1986 | Active |
| J9151 | Injection, daunorubicin citrate, liposomal formulation, 10 mg | — | Jan 1, 1999 | Ended Dec 31, 2025 |
| J9153 | Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine | $274.300per 1 MG/2.27 MG | Jan 1, 2019 | Active |
| J9155 | Injection, degarelix, 1 mg | $4.509per 1 MG | Jan 1, 2010 | Active |
| J9160 | Injection, denileukin diftitox, 300 micrograms | — | Jan 1, 2001 | Ended Dec 31, 2023 |
| J9161 | Injection, denileukin diftitox-cxdl, 1 mcg | $12.826per 1 MCG | Apr 1, 2025 | Active |
| J9165 | Injection, diethylstilbestrol diphosphate, 250 mg | — | Jan 1, 1988 | Ended Dec 31, 2025 |
| J9171 | Injection, docetaxel, 1 mg | $0.471per 1 MG | Jan 1, 2010 | Active |
| J9172 | Injection, docetaxel (docivyx), 1 mg | $46.193per 1 MG | Jan 1, 2024 | Active |
| J9173 | Injection, durvalumab, 10 mg | $87.658per 10 MG | Jan 1, 2019 | Active |
| J9174 | Injection, docetaxel (beizray), 1 mg | $46.531per 1 MG | Jul 1, 2025 | Active |
| J9175 | Injection, elliotts' b solution, 1 ml | — | Jan 1, 2006 | Active |
| J9176 | Injection, elotuzumab, 1 mg | $8.188per 1 MG | Jan 1, 2017 | Active |